|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Citation** | **Patients (n)** | **Specific Treatments** | | | | | | | | | | | | |
| Oseltamivir | Ribavirin + IFN α2a | Ribavirin | IFN α2a | IFN α2b | Ribavirin + IFN β1a | IFN β1a | Steroids | Convales. Plasma | MMF | Azithro-mycin | IVIG | Lopinavir/Ritonavir |
| **Non-Randomized, Single-Arm Intervention Study with Concurrent Comparisons** | | | | | | | | | | | | | | |
| Arabi et al. 201710 | 309 | 169 (55%) | 111 (36%) | 16 (5%) | 8 (3%) | 0 | 0 | 0 | 151 (49%)  NS 114 (76%) | 0 | 0 | 0 | 0 | 0 |
| **Non-Randomized, Single-Arm Intervention Study with Historical Comparisons** | | | | | | | | | | | | | | |
| Omrani et al. 201414 | 44 | 33 (73%) | N/A | 20 (46%) | 20 (46%) | 0 | 0 | 0 | 23 (52%) | 0 | 0 | 0 | 0 | 0 |
| Shalhoub et al. 201515 | 32 | 0 | N/A | 13 (41%)  NS 11 (85%) | 13 (41%)  NS 11 (85%) | 0 | 11 (34%)  NS 7 (64%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alshahrani et al. 20187 | 35 | 0 | 11 (82% ECMO)  4 (24% no ECMO) | 3 (18% ECMO)  0 (no ECMO) | 0 | 0 | 0 | 0 | 9 (53% ECMO)  13 (72% no ECMO) | 0 | 0 | 0 | 0 | 0 |
| **Prospective Cohort Study** | | | | | | | | | | | | | | |
| Hong et al. 201811 | 30 | 0 | N/A | 30 (100%)  NS 6 (20%) | 30 (100%)  NS 6 (20%) | 0 | 0 | 0 | 1 (3%)  NS 1 (100%) | 2 (7%)  NS 1 (100%) | 0 | 0 | 3 (10%)  NS 3 (100%) | 0 |
| Al Hameed et al. 20163 | 8 | 8 (100%)  NS 5 (63%) | N/A | 8 (100%)  NS 5 (63%) | 8 (100%)  NS 5 (63%) | 0 | 0 | 0 | 8 (100%)  NS 5 (63%) | 0 | 0 | 0 | 0 | 0 |
| **Retrospective Cohort Study** | | | | | | | | | | | | | | |
| Arabi et al. 20178 | 330 | 177 (54%)  NS 112 (63%) | 115 (35%)  NS 85 (74%) | 18 (5.5%)  NS 11 (61%) | 9 (3%)  NS 8 (89%) | 0 | 0 | 0 | 177 (54%)  NS 133 (75%) | 0 | 0 | 0 | 23 (7%)  NS 16 (70%) | 0 |
| Almekhlafi et al. 20166 | 31 | 20 (65%)  NS 15 (75%) | N/A | 13 (42%)  NS 9 (69%) | 13 (42%)  NS 9 (69%) | 0 | 0 | 0 | 8 (26%)  NS 6 (75%) | 0 | 0 | 0 | 0 | 0 |
| Sherbini et al. 201716 | 29 | 0 | 0 | 10 (35%)  NS 3 (30%) | 19 (66%)  NS 6 (32%) | 0 | 0 | 0 | 29 (100%)  NS 10 (35%) | 0 | 0 | 19 (66%)  NS 6 (32%) | 0 | 0 |
| Khalid I et al. 201612 | 14 | 7 (50%) | N/A | 11 (79%)  NS 6 (55%) | 11 (79%)  NS 6 (55%) | 0 | 0 | 0 | 14 (100%)  NS 9 (64%) | 0 | 0 | 0 | 0 | 0 |
| Al Ghamdi et al. 20162 | 51 | 0 | N/A | 19 (38%)  NS 6 (32%) | 8 (16%)  NS 2 (25%) | 0 | N/A | 23 (45%)  NS 5 (22%) | 5 (10%)  NS 3 (60%) | 0 | 8 (16%)  NS 0 (0%) | 0 | 0 | 0 |
| Al Dorzi et al. 20161 | 63 (8 HCWs) | 0 | N/A | 0 | 0 | 0 | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Case Series without Evaluation of Treatment** | | | | | | | | | | | | | | |
| Al Tawfiq et al. 20144 | 5 | 5 (100%)  NS 5 (100%) | N/A | 5 (100%)  NS 5 (100%) | 0 | 5 (100%)  NS 5 (100%) | N/A | 0 | 5 (100%)  NS 5 (100%) | 0 | 0 | 0 | 0 | 0 |
| Arabi et al. 20149 | 12 | 7 (58%) | N/A | 0 | 0 | 0 | 0 | 0 | 10 (83%) | 0 | 0 | 0 | 1 (8%) | 0 |
| Alhumaid et al. 20185 | 107 | 13 (12%) | N/A | 61 (57%) | 47 (43%) | 54 (51%) | N/A | 48 (45%) | 24 (22%) | 14 (13%) | 22 (21%) | 59 (55%) | 33 (31%) | 41 (38%) |
| Khalid M et al. 201413 | 6 | 0 | N/A | 6 (100%)  NS 3 (50%) | 6 (100%)  NS 3 (50%) | 0 | 0 | 0 | 1 (17%)  NS 0 (0%) | 0 | 0 | 0 | 0 | 0 |

**Table 1:** Summary of specific treatments used by clinicians for the treatment of MERS-CoV in humans in each of the studies. Number of patients who did not survive (NS) and received each therapy reported where available.

*NS = non-survivors, MMF = Mycophenolate mofetil, IFN = interferon, IVIG = intravenous immunoglobulins, NIPPV = non-invasive positive pressure ventilation, ECMO = extra-corporeal membrane oxygenation, RRT = renal replacement therapy*